Paraneoplastic and idiopathic autoimmune neurologic disorders: Approach to diagnosis and treatment

Sean J Pittock, Jacqueline Palace

Research output: Chapter in Book/Report/Conference proceedingConference contribution

6 Citations (Scopus)

Abstract

Autoimmune neurology is a rapidly emerging new subspecialty that encompasses the diagnosis and treatment of neurologic disorders with an autoimmune (paraneoplastic or noncancer-associated) basis. The last decade has seen a dramatic rise in the discovery of neural-specific autoantibodies and their target antigens. Laboratory testing, on a service basis, is now available for most of these neural-specific autoantibodies and they serve as diagnostic markers, in some instances directing the physician toward specific cancer types (e.g., N-methyl-. d-aspartate receptor antibodies for teratoma; CRMP5-IgG for small-cell cancer) and assisting in therapeutic decision making. Antibodies targeting intracellular proteins (nuclear and intracytoplasmic enzymes, transcription factors, and RNA binding proteins) serve as markers of cytotoxic effector T-cell-mediated injury and are generally poorly responsive to immunotherapy. By contrast, antibodies targeting plasma membrane proteins that are extracellular and accessible (neurotransmitter receptors, ion channels, water channels, and channel-complex proteins) may act as pathogenic effectors and often imply immunotherapy responsiveness. Magnetic resonance imaging, electrophysiologic studies, functional imaging, and neuropsychologic evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured.

Original languageEnglish (US)
Title of host publicationAutoimmune Neurology, 2016
PublisherElsevier
Pages165-183
Number of pages19
Volume133
ISBN (Print)9780444634320
DOIs
StatePublished - 2016

Publication series

NameHandbook of Clinical Neurology
Volume133
ISSN (Print)00729752
ISSN (Electronic)22124152

Fingerprint

Nervous System Diseases
Immunotherapy
Autoantibodies
Antibodies
Aquaporins
Neurotransmitter Receptor
RNA-Binding Proteins
Teratoma
Protein Transport
Neurology
Nuclear Proteins
Neurologic Manifestations
Ion Channels
Blood Proteins
Neoplasms
Decision Making
Membrane Proteins
Transcription Factors
Therapeutics
Immunoglobulin G

Keywords

  • Autoantibodies
  • Autoimmune
  • Diagnosis
  • Paraneoplastic
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Pittock, S. J., & Palace, J. (2016). Paraneoplastic and idiopathic autoimmune neurologic disorders: Approach to diagnosis and treatment. In Autoimmune Neurology, 2016 (Vol. 133, pp. 165-183). (Handbook of Clinical Neurology; Vol. 133). Elsevier. https://doi.org/10.1016/B978-0-444-63432-0.00010-4

Paraneoplastic and idiopathic autoimmune neurologic disorders : Approach to diagnosis and treatment. / Pittock, Sean J; Palace, Jacqueline.

Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. p. 165-183 (Handbook of Clinical Neurology; Vol. 133).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Pittock, SJ & Palace, J 2016, Paraneoplastic and idiopathic autoimmune neurologic disorders: Approach to diagnosis and treatment. in Autoimmune Neurology, 2016. vol. 133, Handbook of Clinical Neurology, vol. 133, Elsevier, pp. 165-183. https://doi.org/10.1016/B978-0-444-63432-0.00010-4
Pittock SJ, Palace J. Paraneoplastic and idiopathic autoimmune neurologic disorders: Approach to diagnosis and treatment. In Autoimmune Neurology, 2016. Vol. 133. Elsevier. 2016. p. 165-183. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-444-63432-0.00010-4
Pittock, Sean J ; Palace, Jacqueline. / Paraneoplastic and idiopathic autoimmune neurologic disorders : Approach to diagnosis and treatment. Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. pp. 165-183 (Handbook of Clinical Neurology).
@inproceedings{b0d7c108651d45daa27bbf6929db67ca,
title = "Paraneoplastic and idiopathic autoimmune neurologic disorders: Approach to diagnosis and treatment",
abstract = "Autoimmune neurology is a rapidly emerging new subspecialty that encompasses the diagnosis and treatment of neurologic disorders with an autoimmune (paraneoplastic or noncancer-associated) basis. The last decade has seen a dramatic rise in the discovery of neural-specific autoantibodies and their target antigens. Laboratory testing, on a service basis, is now available for most of these neural-specific autoantibodies and they serve as diagnostic markers, in some instances directing the physician toward specific cancer types (e.g., N-methyl-. d-aspartate receptor antibodies for teratoma; CRMP5-IgG for small-cell cancer) and assisting in therapeutic decision making. Antibodies targeting intracellular proteins (nuclear and intracytoplasmic enzymes, transcription factors, and RNA binding proteins) serve as markers of cytotoxic effector T-cell-mediated injury and are generally poorly responsive to immunotherapy. By contrast, antibodies targeting plasma membrane proteins that are extracellular and accessible (neurotransmitter receptors, ion channels, water channels, and channel-complex proteins) may act as pathogenic effectors and often imply immunotherapy responsiveness. Magnetic resonance imaging, electrophysiologic studies, functional imaging, and neuropsychologic evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured.",
keywords = "Autoantibodies, Autoimmune, Diagnosis, Paraneoplastic, Treatment",
author = "Pittock, {Sean J} and Jacqueline Palace",
year = "2016",
doi = "10.1016/B978-0-444-63432-0.00010-4",
language = "English (US)",
isbn = "9780444634320",
volume = "133",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "165--183",
booktitle = "Autoimmune Neurology, 2016",

}

TY - GEN

T1 - Paraneoplastic and idiopathic autoimmune neurologic disorders

T2 - Approach to diagnosis and treatment

AU - Pittock, Sean J

AU - Palace, Jacqueline

PY - 2016

Y1 - 2016

N2 - Autoimmune neurology is a rapidly emerging new subspecialty that encompasses the diagnosis and treatment of neurologic disorders with an autoimmune (paraneoplastic or noncancer-associated) basis. The last decade has seen a dramatic rise in the discovery of neural-specific autoantibodies and their target antigens. Laboratory testing, on a service basis, is now available for most of these neural-specific autoantibodies and they serve as diagnostic markers, in some instances directing the physician toward specific cancer types (e.g., N-methyl-. d-aspartate receptor antibodies for teratoma; CRMP5-IgG for small-cell cancer) and assisting in therapeutic decision making. Antibodies targeting intracellular proteins (nuclear and intracytoplasmic enzymes, transcription factors, and RNA binding proteins) serve as markers of cytotoxic effector T-cell-mediated injury and are generally poorly responsive to immunotherapy. By contrast, antibodies targeting plasma membrane proteins that are extracellular and accessible (neurotransmitter receptors, ion channels, water channels, and channel-complex proteins) may act as pathogenic effectors and often imply immunotherapy responsiveness. Magnetic resonance imaging, electrophysiologic studies, functional imaging, and neuropsychologic evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured.

AB - Autoimmune neurology is a rapidly emerging new subspecialty that encompasses the diagnosis and treatment of neurologic disorders with an autoimmune (paraneoplastic or noncancer-associated) basis. The last decade has seen a dramatic rise in the discovery of neural-specific autoantibodies and their target antigens. Laboratory testing, on a service basis, is now available for most of these neural-specific autoantibodies and they serve as diagnostic markers, in some instances directing the physician toward specific cancer types (e.g., N-methyl-. d-aspartate receptor antibodies for teratoma; CRMP5-IgG for small-cell cancer) and assisting in therapeutic decision making. Antibodies targeting intracellular proteins (nuclear and intracytoplasmic enzymes, transcription factors, and RNA binding proteins) serve as markers of cytotoxic effector T-cell-mediated injury and are generally poorly responsive to immunotherapy. By contrast, antibodies targeting plasma membrane proteins that are extracellular and accessible (neurotransmitter receptors, ion channels, water channels, and channel-complex proteins) may act as pathogenic effectors and often imply immunotherapy responsiveness. Magnetic resonance imaging, electrophysiologic studies, functional imaging, and neuropsychologic evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured.

KW - Autoantibodies

KW - Autoimmune

KW - Diagnosis

KW - Paraneoplastic

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84978438113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978438113&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63432-0.00010-4

DO - 10.1016/B978-0-444-63432-0.00010-4

M3 - Conference contribution

C2 - 27112677

AN - SCOPUS:84978438113

SN - 9780444634320

VL - 133

T3 - Handbook of Clinical Neurology

SP - 165

EP - 183

BT - Autoimmune Neurology, 2016

PB - Elsevier

ER -